Compare the Safety and Effectiveness of Genoss® DCB and SeQuent® Please NEO in Chinese Patients with Coronary ISR

A Prospective, Multicenter, Randomized Controlled Trials to Evaluate the Safety and Effectiveness of Genoss® DCB Versus SeQuent® Please NEO in Patients with Coronary In-stent Restenosis (ISR)

The purpose of this study is to evaluate the safety and effectiveness of Genoss® DCB by demonstrating non-inferiority in patients with in-stent restenosis (ISR) compared with a product of the same category (Sequent® Please NEO).

The experimental group was treated with Genoss® DCB, and the control group was treated with SeQuent® Please NEO.

In this study, the end point of 9 months after procedure was used as the main endpoint to evaluate the effectiveness of Paclitaxel coated PTCA balloon catheter. The safety of the catheter was evaluated by cardiovascular adverse events.

Study Overview

• Status: Completed
• Conditions: Coronary Artery Disease
• Intervention / Treatment: Device: Paclitaxel Coated PTCA Balloon Catheter(Genoss® DCB); Device: Paclitaxel Coated PTCA Balloon Catheter(SeQuent® Please NEO)

Detailed Description

In a randomized controlled trials to compare with the same-category medical device (Sequent® Please NEO), 224 patients with in-stent restenosis (ISR) were recruited from a total of 13 institutions, and the enrolled subjects were 1: 1 through randomization. The ratio was assigned to the test group(Genoss® DCB) and the control group(SeQuent® Please NEO), and each of the test or control devices was assigned to receive the procedure.

All patients were followed up 30 days, 6 months, 9 months, 1 year and 2 years after procedure, and angiographic follow-up was performed 9 months after procedure.

• Study Type: Interventional
• Enrollment (Actual): 224
• Phase: Not Applicable

Contacts and Locations

Study Locations

• China
  • Shaanxi
    • Xi'an, Shaanxi, China, 710032
      • Department of Cardiology, First Affiliated Hospital of Air Force Medical University of Chinese PLA

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

Subject related inclusion criteria

• Age≥18 years old & ≤80 years old.
• Patients with stable angina pectoris, unstable angina pectoris, stable acute myocardial infarction or confirmed silent myocardial ischemia.
• Patients who can understand the purpose of the study and voluntarily participate in and sign informed consent.
• It is suitable for patients undergoing percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG).

Desease related inclusion criteria

• The target lesions were in stent restenosis: Mehran type I, II and III stenosis.
• The stenosis rate of target lesion diameter was more than 70%, or more than 50%, accompanied by objective evidence of ischemia (such as stress electrocardiogram, myocardial perfusion imaging, FFR, etc.)
• The reference vessel diameter of the target lesion was 2.0-4.0 mm, and the target lesion length was less than or equal to 26 mm.
• It is expected that no more than two drug balloons will be used in each subject, and each target lesion can be covered by one drug balloon.
• At most 2 primary lesions need interventional treatment, and the distance from the target lesion is more than or equal to 10 mm, and can be successfully treated before the intervention of the target lesion.

Exclusion Criteria:

Subject related exclusion criteria

• A woman who is pregnant, lactating, or planning a pregnancy.
• Patients with cardiogenic shock, acute infection, known bleeding or coagulation disorder, or history of cerebral hemorrhage, subarachnoid hemorrhage, active peptic ulcer and gastrointestinal bleeding within 3 months before operation.
• Patients who are known to be allergic to aspirin, clopidogrel, ticagrelor, heparin, contrast agent, paclitaxel, or have contraindications to aspirin, clopidogrel or ticagrelor.
• Patients with acute myocardial infarction within 1 week before operation.
• Patients with Takayasu arteritis.
• Left ventricular ejection fraction ≤ 30%.
• Acute or chronic renal insufficiency (serum creatinine > 2.0mg/dl or 178 μ mol / L).
• Patients with life expectancy less than 1 year.
• Patients participating in clinical trials of other drugs or medical devices.
• According to the researcher's judgment, the patient's clinical condition is not suitable for this study, or the patient is expected to be unable to complete the follow-up study according to the protocol.

Disease related exclusion criteria

• The target lesion was total occlusion (Mehran type IV).
• The target and non target lesions were left main artery lesions.
• The target lesions were ostial, pontine and bifurcated lesions with branch diameter ≥ 2.5mm.
• Three vessel disease requiring treatment.
• More than 3 lesions (including target lesions and non target lesions) need to be treated in target vessels.
• ISR lesions intervened within 6 months before operation.
• Angiography confirmed thrombus in the target vessel.
• The target vessel is severely calcified, tortuous and angulated, so it is expected that the drug balloon catheter will not pass successfully.
• The lesions that could not be pre dilated successfully were grade C or above dissection after pre dilation, or residual stenosis > 30%, or TIMI blood flow < grade III.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Genoss® DCB; Paclitaxel Coated PTCA Balloon Catheter	Device: Paclitaxel Coated PTCA Balloon Catheter(Genoss® DCB); Drug Coated Balloon
Active Comparator: SeQuent® Please NEO; Paclitaxel Coated PTCA Balloon Catheter	Device: Paclitaxel Coated PTCA Balloon Catheter(SeQuent® Please NEO); Drug Coated Balloon

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
In-segment late lumen loss after procedure	In-segment late lumen loss between test group(Genoss DCB) and control group(Sequent Please) evaluated by quantitiative coronary analysis in patients with ISR	at 9 months after procedure

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Device-oriented compoiste endpoint (DOCE)	DOCE is defined as a composite of cadiac death, target vessel-related myocardial infarction (TV-MI), and ischemia-driven target lesion revascularization (ID-TLR)	at 30 days, 6 months, 9 months, 12 months and 24 months after procedure
Patient-oriented composite endpoint (POCE)	POCE is defined as a composite of all-cause death, any myocardial infarction, any revascularization	at 30 days, 6 months, 9 months, 12 months, and 24 months after procedure
Retenosis rate		at 9 months after procedure
Stent thrombosis by ARC definition		at 6 months, 9 months, 12 months, 24 months after procedure

Collaborators and Investigators

• Sponsor: Genoss Co., Ltd.
• Investigators: Principal Investigator: Ling Tao, Department of Cardiology, First Affiliated Hospital of Air Force Medical University of Chinese PLA

Study record dates

Study Major Dates

• Study Start (Actual): January 30, 2021
• Primary Completion (Actual): December 20, 2023
• Study Completion (Actual): May 30, 2024

Study Registration Dates

• First Submitted: February 19, 2021
• First Submitted That Met QC Criteria: February 22, 2021
• First Posted (Actual): February 23, 2021

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: February 19, 2025
• Last Verified: February 1, 2025

More Information

Terms related to this study

• Keywords: In-Stent Restenosis
• Additional Relevant MeSH Terms: Vascular Diseases; Cardiovascular Diseases; Heart Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Coronary Disease; Myocardial Ischemia; Coronary Artery Disease; Antineoplastic Agents; Molecular Mechanisms of Pharmacological Action; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Antineoplastic Agents, Phytogenic; Albumin-Bound Paclitaxel; Paclitaxel
• Other Study ID Numbers: CIP-DS1001-C

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No